Drug Action
Vismodegib is a hedgehog pathway inhibitor.
PDF page 1088
Loading InternPractice…
Drug reference
Vismodegib is a hedgehog pathway inhibitor.
PDF page 1088
Symptomatic metastatic basal cell carcinoma | Locally advanced basal cell carcinoma not appropriate for surgery or radiotherapy ▶BY MOUTH ▶Adult: 150 mg once daily
PDF page 1088
Prescribers and pharmacists must comply with prescribing and dispensing restrictions as specified in the manufacturer’s Pregnancy Prevention Programme, and ensure that the patient fully acknowledges the programme’s pregnancy prevention measures—consult product literature for further information.
PDF page 1089
NICE decisions ▶Vismodegib for treating basal cell carcinoma (November 2017) NICE TA489 Vismodegib is not recommended within its marketing authorisation for treating symptomatic metastatic basal cell carcinoma, or locally advanced basal cell carcinoma that is inappropriate for surgery or radiotherapy, in adults. Patients whose treatment was started within the NHS before this guidance was published should have the option to continue treatment, without change to their funding arrangements, until they and their NHS clinician consider it appropriate to stop. www.nice.org.uk/guidance/TA489
PDF page 1089
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES See Cytotoxic drugs p. 938.
PDF page 1088
→Appendix 1: vismodegib
PDF page 1088
▶Common or very common Alopecia. amenorrhoea. appetite decreased. arthralgia. asthenia. constipation. dehydration. diarrhoea. gastrointestinal discomfort. hair growth abnormal. muscle complaints. nausea. pain. skin reactions. taste altered. vomiting. weight decreased ▶Frequency not known Epiphyses premature fusion
PDF page 1088
For women of child- bearing potential, pregnancy must be excluded before initiation of treatment, and monthly during treatment. Women must use two contraceptive methods (including one highly effective method and one barrier method) during treatment and for 24 months after the final dose of vismodegib. Men must use a condom during treatment and for 2 months after the final dose.
PDF page 1089
Important: teratogenic risk—may cause severe birth defects and embryo-fetal death.
PDF page 1089
Avoid during treatment and for 24 months after final dose.
PDF page 1089
No information available— manufacturer advises caution in severe impairment.
PDF page 1089
There can be variation in the licensing of different medicines containing the same drug. Capsule CAUTIONARY AND ADVISORY LABELS 25 ▶Erivedge (Roche Products Ltd) Vismodegib 150 mg Erivedge 150mg capsules | 28 capsule P £6,285.00 (Hospital only) ANTINEOVASCULARISATION DRUGS › VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS
PDF page 1089
Conception and contraception Counselling on pregnancy and contraception advised. Patients must comply with the manufacturer’s pregnancy prevention programme.
PDF page 1089
150 mg once daily
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1088